RNA-seq analysis of human ER− breast cancer cells treated with buparlisib (PI3Kα/β/δ/γ inhibitor) revealed up-regulation of Wnt pathway gene expression including increased expression of Wnt ligands (WNT3, WNT7B, WNT9A, WNT10B), receptor complex proteins (FZD1, FZD2, FZD4, FZD7, FZD9, LRP4, LRP6, PTK7) and CTNNB1 mRNA [106]. Here, WNT3 is linked to breast carcinoma.